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1.  INTRODUCTION  AND  THE  AIM  OF  
THE WORK 
 Rhodanine (2-thioxo-1,3-thiazolidin-4-one) was first prepared by Nencki 
in 1877 1. Since that time various derivatives of rhodanine and N-substituted 
rhodanines were prepared. Some of them have also been screened for their 
biological activities 2 – 4. 
 Boyd [5] searched various databases to obtain an indication of how 
common the rhodanine ring is. From the database search results that the 
prevalence of rhodanine-containing compounds of pharmaceutical interest is very 
small despite the fact that the compounds exhibit a wide variety of bioactivity. 
Epalrestat is the only derivative of rhodanine that has been used clinically. It is an 
aldose reductase inhibitor and is used to slow eye damage associated with diabetes 
















 The rarity of clinically effective compounds with a rhodanine ring can be 
viewed in two ways. An optimistic believer in drug discovery by serendipity 
might see that the rhodanines are a relatively unexploited structural motif and 
therefore have the potential to lead to novel, patentable compounds. On the other 
hand, a pragmatist looking rationally at the track record might see the rhodanines 
as a motif that has yielded little useful information to date and is therefore 
unlikely to do so in future [5, 6]. 
 Recent studies performed at the Department of Pharmaceutical Chemistry 
and Drug Control of the Faculty of Pharmacy in Hradec Králové showed that 
condensation product of rhodanine with acetylpyrazines were practically 
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ineffective in antifungal, antimycobacterial, antiproliferative assays [7], but 
benzylidenerhodanines derived from ring substituted benzaldehydes exhibited 
antifungal properties (MIC = 15.62 – 250 μmol.l
-1
). 5-Benzylidene-2-thioxo-1,3-
thiazolidine-4-one and 5-(4-chlorobenzylidene)-2-thioxo-1,3-thiazolidine-4-one 









5-benzylidene-2-thioxo-1,3-thiazolidine-4-one: R = H 
5-(4-chlorobenzylidene)-2-thioxo-1,3-thiazolidine-4-one: R = Cl 
 
 The aim of my diploma thesis is to prepare additional condensation 
products of rhodanine with aldehydes. The compounds will then be submitted to 





2.  THEORETICAL  PART 
2.1. Mycobacterial diseases 
 There are more than 70 species of mycobacteria. Of these, two are major 
pathogens – Mycobacterium tuberculosis (Koch, 1882) and Mycobacterium 
leprae (Hansen, 1874). The remaining mycobacteria are environmental organisms 
– collectively known as MOTTS (Mycobacteria Other Than Tuberculosis), NTM 
(Non-Tuberculous Mycobacteria) or atypical mycobacteria.  NMT, especially 
Mycobacterium avium complex, are facultative human pathogens that are 
responsible not only for disseminated disease in patients with AIDS but also for 
various opportunistic infections affecting organs (e.g. lung, skin, eyes) of people 
without AIDS [9 – 13]. 
 
2.2. Tuberculosis (TB) and possibilities manage it 
 
2.2.1. The disease tuberculosis 
 Tuberculosis is an infectious disease caused by the microorganism 
Mycobacterium tuberculosis. It can affect several organs of the human body, 
including the brain, the kidneys and the bones; but most commonly it affects the 
lungs (Pulmonary Tuberculosis). The first stage of the infection usually lasts for 
several months. During this period, the body´s natural defenses (immune system) 
resist the disease, and most or all of the bacteria are walled in by a fibrous capsule 
that develops around the area. Before the initial attack is over, a few bacteria may 
escape into the bloodstream and be carried elsewhere in the body, where they are 
again walled in. In many cases, the disease never develops beyond this stage – and 
is referred to as TB infection. If the immune system fails to stop the infection and 
it is left untreated, the disease progresses to the second stage, active disease. 
There, the germ multiplies rapidly and destroys the tissues of the lungs (or the 
other affected organ). In some cases, the disease, although halted at first, flares up 
after a latent period. Sometimes, the latent period is many years, and the bacteria 




 The second stage of the disease is manifested by destruction or 
"consumption" of the tissues of the affected organ. When the lung is affected, it 
results in diminished respiratory capacity, associated with other symptoms; when 
other organs are affected, even if treated adequately, it may leave permanent, 
disabling scar tissue [14]. 
 
2.2.2. Mycobacterium tuberculosis  
 Mycobacterium tuberculosis is a fairly large nonmotile rod-shaped 
bacterium distantly related to the Actinomycetes. The rods are 2 – 4 μm in length 
and 0.2 – 0.5 μm in width. Chains of cells in smears made from in vitro-grown 
colonies often form distinctive serpentine cords. This observation was first made 
by Robert Koch who associated cord factor with virulent strains of the bacterium.  
It is an obligate aerobe. For this reason, in the classic case of tuberculosis, the 
M. tuberculosis complexes are always found in the well-aerated upper lobes of the 
lungs. The bacterium is a facultative intracellular parasite, usually of 
macrophages, and has a slow generation time, 15 – 20 hours, a physiological 
characteristic that may contribute to its virulence.  
 Two media are used to grow M. tuberculosis. Middlebrook´s medium 
which is an agar based medium and Lowenstein-Jensen medium which is an egg 
based medium. M. tuberculosis colonies are small and buff colored when grown 
on either medium (Figure 1). Both types of media contain inhibitors to keep 
contaminants from out-growing M. tuberculosis. It takes 4 – 6 weeks to get visual 




Figure 1. Colonies of M. tuberculosis on Lowenstein-Jensen medium [15] 
 
 The cell wall structure of M. tuberculosis deserves special attention 
because it is unique among procaryotes and it is a major determinant of virulence 
for the bacterium. The cell wall complex contains peptidoglycan, but otherwise it 
is composed of complex lipids. Over 60% of the mycobacterial cell wall is lipid. 
The lipid fraction of M. tuberculosis cell wall consists of three major components: 
 Mycolic acids are unique α-branched lipids found in cell walls of 
Mycobacterium and Corynebacterium. They make up 50% of the dry 
weight of the mycobacterial cell envelope. Mycolic acids are strong 
hydrophobic molecules that form a lipid shell around the organism and 
affect permeability properties at the cell surface. Mycolic acids are 
thought to be a significant determinant of virulence in M. tuberculosis. 
Probably, they prevent attack of the mycobacteria by cationic proteins, 
lysozyme and oxygen radicals in the phagocytic granule. They also 
protect extracellular mycobacteria from complement deposition in 
serum.  
 Cord factor is responsible for the serpentine cording mentioned 
above. Cord factor is toxic to mammalian cells and is also an inhibitor 
of polymorphonuclear migration. Cord factor is most abundantly 
produced in virulent strains of M. tuberculosis. 
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 Wax-D in the cell envelope is the major component of Freund´s 
complete adjuvant. 
The high concentration of lipids in the cell wall of M. tuberculosis has been 
associated with these properties of the bacterium:  
 Impermeability to stains and dyes  
 Resistance to many antibiotics  
 Resistance to killing by acidic and alkaline compounds  
 Resistance to osmotic lysis via complement deposition  
 Resistance to lethal oxidations and survival inside of macrophages 
[15]. 
 
2.2.3. Management of tuberculosis  
 The following approaches have been in practice or studied as potential 
measures in attempting to control tuberculosis:  




2.2.3.5. Chemotherapy [16]. 
 
2.2.3.1. The sanatorium with fresh air, cleanliness, and a nutritious diet 
 The introduction of the sanatorium cure provided the first real step against 
TB. Hermann Brehmer, a Silesian botany student suffering from TB, was 
instructed by his doctor to seek out a healthier climate. He traveled to the 
Himalayan mountains where he could pursue his botanical studies while trying to 
rid himself of the disease. He returned home cured and began to study medicine. 
In 1854, he presented his doctoral dissertation bearing the auspicious title, 
Tuberculosis is a Curable Disease. In the same year, he built an institution in 
Gorbersdorf where, in the midst of fir trees, and with good nutrition, patients were 
exposed on their balconies to continuous fresh air. This setup became the 
blueprint for the subsequent development of sanatoria, a powerful weapon in the 




 Active immunization is one of the essential components to control TB, 
although vaccination is ineffective nowadays. Until now one billion people have 
been vaccinated with BCG (Bacilli Calmette-Guerin). In general, the efforts to 
make new four classes of vaccines candidates are being worked on: the rationally 
attenuated strains of M. tuberculosis, BCG vaccines, protein subunit vaccines, and 
nucleic acid vaccines [16]. 
 The rationally attenuated strains of M. tuberculosis 
The manipulation of M. tuberculosis chromosomes generates bacterial 
strains, which lack the pathogenicity but elicit a protective immune 
response. 
 BCG vaccines  
Advances in the discovery and characterization of genes and antigens 
of M. tuberculosis had led to substantial progress toward the 
development of improved vaccines since BCG vaccines were first used 
successfully. The cheap BCG vaccines with minor side effects can 
safely be given to children. It is proven now that BCG does have some 
protective effects in children and is effective against meningitis TB, 
but it does not prevent the emergence of pulmonary TB, particularly in 
the adulthood. 
Protein subunit vaccines 
Purified proteins as vaccine candidates have several advantages over 
attenuated organisms. They are inherently safe and have no propensity 
to cause disease, which is an important consideration when vaccinated 
individuals have been exposed to HIV. The efficacy of such vaccines 
has been demonstrated in mice and guinea pigs. 
 Nucleic acid vaccines 
The hypothesis that naked DNA vaccines and DNA encoding 
influenza nucleoprotein lend immunity to influenza in mice has been 
applied to M. tuberculosis also. Many nucleic acid vaccines have 




2.2.3.3. Genomics  
 The most significant developments in the area of TB are perhaps the 
sequencing of the mycobacterial genome. Among the estimated 4500 genes, every 
drug target and every antigen or protein elicits an immune response. Among them 
40% of is known, another 44% have some sequence homology, whereas function 
of 16% are completely unknown, and they may account for specific mycobacterial 
functions. 
 
2.2.3.4. Immunotherapy  
 Immunotherapy is a therapeutic means whereby the immune system is 
stimulated by the injection of inactivated mycobacteria, resulting in the activation 
of Th1 cells and inactivation of Th2 cells, the two kinds of helper cells. Cell 
mediated immune (CMI) and delayed type of hypersensitive (DTH) responses 
play very important roles in host during M. tuberculosis infection. Several studies 
on the effectiveness of Mycobacterium vaccae, as an immunotherapeutic agent for 
TB control have recently been carried out. It is thought to be a powerful Th1 
adjuvant and has a beneficial effect with enough evidence of its use as an 
immunotherapeutic agent [16]. 
 
2.2.3.5. Chemotherapy 
 Chemoterapy of TB started in 1940´s. In 1943, anti-TB research resulted 
in discovery of the active anti-TB agents, and strategies have been devised to treat 
TB from time to time. A number of agents have been discovered since then, 
including para-aminosalicylic acid (PAS), isoniazid (INH), pyrazinamide (PZA), 
cycloserine, ethionamide, rifampicin (RMP), and ethambutol. The majority of 
these drugs were discovered through broad random screening. Very little 
optimization was undertaken. As no biochemical tools to study biochemical 
reactions were known at that time, the modifications were made without any 
regard to drug targets.. This lack of understanding of drug action because of 
ignorance in the biochemistry of mycobacterium and urgency to develop drugs 
against this devastating disease led to random screening of compound libraries in 
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fact, among other reasons, the difficulty in manipulating M. tuberculosis has 
hindered efforts to delineate the mode of the action of these agents. 
 Recent improvements in biological techniques have allowed mechanism of 
action of many of these agents to be uncovered and more carefully studied. 
Current treatment involve multiple drug regimens that extend for months at the 
time, and pharmacology of these treatments regimens can be complex, specially 
for the treatment of multidrug resistant tuberculosis (MDR TB) [16]. 
 Generally the targets, for an anti-TB drug, involve the biosynthetic 
pathways which are involved in the production of macromolecules (the proteins, 
the nucleic acids, or cell wall polymers). Many well known anti-TB drugs target 
the biosynthesis of these macromolecules. The recent development in genetic 
engineering of M. tuberculosis have now offered many targets to be validated and 
screen libraries of compounds against them to develop new anti-TB agents. In 
selecting targets for anti-TB agents, it is advantageous to avoid targets that are 
close to counterparts in mammalian cells. It is also desirable that new targets 
should be specific to mycobacteria to limit the transfer of resistant factors from 
other bacteria. Further, new drugs must act on a target that is essential for 
bacterial survival, and ideally they should be active against mycobacterium 
throughout their growth cycle both inside and outside mammalian cells during 
infection.  
The following targets for anti-TB drugs have been studied: 
 
 Protein Synthesis  
Streptomycin, an aminoglycoside for widespread use in the treatment 
of TB, disrupts the protein synthesis in bacteria. Streptomycin 
resistance in M. tuberculosis is because of mutation altering the 16s 
ribosomal subunit in the RNA molecule. Most of aminoglycosides act 
through this mechanism. 
 Nucleic Acids  
Sulphonamides, the structural analogs of p-aminobenzoic acid, inhibit 
biosynthesis of tetrahydrofolic acid, and thereby block the production 
of purine and pyrimidine bases required for nucleic acids synthesis in 
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microbes. A detailed study of enzymes involved in tetrahydrofolate 
biosynthesis may lead to a rational design of new and novel anti-TB 
drugs. 
 DNA Topoisomerases  
Another promising target is DNA topoisomerase particularly DNA 
gyrase, a type 2 topoisomerase. Biosynthesis of nucleotides has 
recently been reported to be a good target particularly for TB in HIV-
cases. Very recently, thymididne monophosphate kinase (dTMKase) 
has been suggested as a validated target to develop new anti-TB 
agents, particularly for the treatment of MDR TB and TB in HIV 
infected patients. 
 Cell Wall Macromolecules Biosynthesis  
Based upon most recent developments in the ultra structure and 
biochemistry of M. tuberculosis, its cell envelope, consisting of three 
structural components, the plasma membrane, the cell wall, and the 
capsule, has been identified as the most important target to develop 
new drugs. Plasma membrane appears to be a typical bacterial 
membrane contributing very little towards the pathological processes 
[16]. 
 Mycolic Acids and Other Lipids  
The cell envelope of M. tuberculosis is based on unusual lipid 
molecules, ranging from inert waxes to biologically-active glycolipids. 
The mycolic acids are high-molecular weight (70 – 90 carbon), 3-
hydroxy fatty acids covalently bound to arabinogalactan, as the 
dominant part of the cell envelope. An initial key mycolic acid 
biosynthetic step is a delta-5 desaturation of tetracosanoate, followed 
by elongation. It was shown that the cyclopropene analogue of Z-
tetracos-5-enoate is a specific inhibitor of mycolic acid biosynthesis, 
establishing the principal that it was possible to target key lipid 
biosynthetic targets. Current studies are aimed at the detailed 
elucidation of the role of the antimycobacterial agent isoxyl in this key 
step. Isoniazid (isonicotinic acid hydrazide) and thiolactomycin are 
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involved in the elongation cycle of mycolic acids and the detailed 
mechanisms of action of these drugs are being studied. The 
translocation of mycolic acids into the cell walls of mycobacteria is 
being studied by designing inhibitors and substrates of the key 
“antigen-85” tranferase [16, 18]. 
 Isocitrate Lyase as a Target for Combating Latent Infection 
An enzyme isocitrate lyase (absent in mammals) responsible for the 
conversion of isocitrate to glyoxylate is a very hot molecule and is 
considered to be a promising target for new drug development for TB. 
It has very attractive feature of being bacterium-specific [16]. 
 
2.2.3.5.1. Current therapy  
 Drugs used to treat TB include broad spectrum and narrow spectrum 
agents, and different drug combinations are used in different types of TB 
discussed briefly below. The aims of the current chemotherapy are: 
 conversion of the sputum cultures to negative in shortest time 
 prevention of emergence of drug resistance 
 asurance of a complete cure without relapse [16]. 
The DOT (Directly Observed Therapy) strategy is actively promoted by the 
World Health Organization (WHO) for TB patients in an effort to control the 
global emergency of TB. DOT means that a supervisor watches the client 
swallowing the medication for all doses over the course of treatment. This ensures 
that a TB client takes the correct drugs, the correct dose, and at the correct times. 
DOT may happen on an inpatient or outpatient basis The DOT supervisor may be 
a health worker or a trained and supervised community member. There must be a 
clearly defined line of accountability between the TB control staff and the person 
administering DOT. It is important to ensure confidentiality and that DOT is 
acceptable to the patient [19]. 
 The first drug shown to be effective was streptomycin, in the late 1940´s. 
Streptomycin is an aminoglycoside antibiotic isolated from Streptomyces griseus. 
It consists of three components, streptidine streptose, and N-methyl-L-
glucosamine. Because of its poor absorbance from the gastrointestinal tract, it is 
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administered intramuscularly and very occasionally by interthecal route. It 
penetrates the inner membrane of M. tuberculosis and binds to the 30S subunit of 
the ribosome. Because of many toxic manifestations on the peripheral and central 
nervous system at higher doses, and hypersensitivity reactions, it is not a drug of 
popular choice. In addition, it was soon found that an initial response was often 
followed by treatment failure, and that drug resistance developed in a high 

























A further advance occurred with the addition of p-aminosalicylic acid (PAS), 
which markedly reduced the development of resistance to streptomycin. For many 
years PAS was considered a first line drug for the chemotherapy of tuberculosis 
and was generally included in combination regimes. However, the introduction of 
more effective and generally better tolerated agents have relegated to an 
alternative drug status [20]. 
 The chemotherapy era, with consistent achievement of high cure rates, 
really began in 1952 with the discovery of isoniazid and its use in combination 
regimens. Isoniazid, a hydrazide of isonicotinic acid, has been one of the most 
effective and most commonly used antituberculous agents. It has potent 
bactericidal activity against all populations of organisms in patient with 
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tuberculosis. It is very inexpensive and relatively safe. Isoniazid continues to be 
1 of 2 drugs, along with rifampicin (rifampin), that are central to treatment of 
tuberculosis. It is the only drug with a well established role in chemoprophylaxis. 
Inhibition of mycolic acid biosynthesis may be a primary action. Isoniazid may 
prevent elongation of the “very-long-chain fatty acid precursors” of mycolic acid. 
Isoniazid also inhibits the first step that is specific for mycolic acid synthesis, a 
desaturase enzyme [16, 20]. 
 While searching for new isoniazide analogs, the antimycobacterial activity 
of pyrazinamide was revealed. No other changes on its molecule lead to 
improving of the antituberculous activity. Pyrazinamide has potent sterilizing 
activity in the acid pH of the intracellular environment and extracellulary in 
highly inflamed tissue. It is well absorbed after peroral administration and 
hydrolyzed by liver to pyrazinoic acid, an active metabolite. Its addition for the 
first 2 months to regimens containing isoniazid and rifampicin appears to be 
essential to achieving very high rates of relapse-free cure. 
The main adverse effect is hepatotoxicity. It is relatively costly in comparison 

















p-aminosalicylic acid isoniazid pyrazinamide 
 
 Ethambutol was introduced in 1962 [17]. It is a synthetic agent, active 
only against dividing mycobacteria. It is the most active member of the group of 
ethylendiamine derivatives, but also compounds with 2-aminopropanol, 
2-aminoisopentanol or 3-amino-2-butanol in their molecules are of some activity. 
Ethambutol posseses optical activity with only R-(+) isomer being of a high 
antituberculous activity. Mechanism of action includes interference with the 
synthesis and stabilization of RNA. Its main use is as a companion drug, to 
18 
 
prevent the development of resistance to more potent agents. It is increasingly 
replacing thioacetazone in countries with high HIV prevalence. The main toxicity 











 Another class of antituberculous drugs includes -CSNH-moiety containing 
compounds. To this group belong thiosemicarbazones (=N-NH-CS-NH2) and 
thioamides (-CS-NH2). Thiosemicarbazones of aliphatic aldehydes or ketones are 
highly toxic compounds, therefore only some thiosemicarbazones of aromatic or 
heterocyclic aldehydes found their place in therapy. Until today, only 
thioacetazone (thiosemicarbazone of 4-acetamidobenzaldehyde) is in practice. It 
is a drug of modest efficacy, but with a role in preventing development of 
resistance to a more potent antituberculous drug. The advantage of this drug is a 
low cost, so it is widely used particularly in countries with very limited resources. 
Among thioamides two therapeutically used drugs – ethionamide and 
prothionamide – belong. They are synthetic derivatives, thioamides of 2-ethyl 
and 2-propylisonicotinic acids. They are considered to be interchangeable. Their 
mechanism of action is similar to that of isoniazid, inhibition of mycolic acid 


















ethionamide: R = C2H5 




 Besides streptomycine, other antibiotics have been found effective against 
mycobateria. Cycloserine is used sometimes as a second-line drug for treatment 







 Nowadays, rifampicin is an essential element of modern short course 
treatment regimens. Because of its activity against non-mycobacterial organisms, 
it has a high potential of misuse in the community, which increase prevalence of 
rifampicin-resistant tuberculosis. Rifamycins bind to the β-subunit of bacterial 
DNA-dependent RNA polymerases to prevent chain initiation. Like isoniazid, 
rifampicin can cause hepatotoxicity, but it is usually well tolerated. The success of 
rifampicin in the treatment of tuberculosis stimulated researchers to manipulate 
the rifamycin molecule to produce other, and possibly better, antibiotics. There 
are two newer ansamycins with antimycobacterial activity. Rifabutin is a 
spiropiperidyl rifamycin derivative that is more active against M. avium complex, 
with a lower MIC and lower natural resistance rate. Rifapentine is generally more 
active against M. tuberculosis than rifampicin although strains resistant to 

























































































 New semisynthetic macrolides, e.g. clarithromycin and azithromycin, 
also exert antimycobacterial activity. These antibiotics bind to high-affinity site in 
the peptidyl t-RNA binding region of the bacterial 50S ribosome subunit, causing 
dissociation of peptidyl-tRNA from ribosomes and inhibition of bacterial protein 
synthesis. They appear to be promising in the treatment of mycobacterial 


























































 Capreomycin is strongly basic peptide isolated from S. capreolus. Four 
capreomycin designated 1A, 1B, 2A, 2B have been isolated. The clinical agent 
contains primarly 1A and 1B. It was released in the early 1970´s exclusively as a 
tuberculostatic drug. It is a second line agent employed in combination with other 





























capreomycin 1A: R = OH 




 Quinolinones exhibit bactericidal effects that involve an interaction of the 
drug with DNA-gyrase and DNA-topoisomerase IV. The new members of this 
group with a heterocyclic ring in position 7 and fluoro-substitution in position 6 
and/or 8 are very active against mycobacteria with low MIC values. 
Ciprofloxacin, ofloxacin and sparfloxacin and moxifloxacin have been used as 
part of multi drug regimes to cure patients infected with M. tuberculosis and M. 




































moxifloxacin  sparfloxacin 
 
 Clofazimine is a phenazine dye used for the treatment of leprosy. It has 
been shown to be active in vitro against M. tuberculosis the drug is only indicated 
as an addition to two or more reliable agents in regimens for multidrug-resistant 
disease. Liposomized, encapsulated clofazimine has been reported to be more 
effective then clofazimine alone in experimental studied in mice [16, 20, 24]. 
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Some clofazimine analogues are currently under study as new potential 














2.2.3.5.2. New structural classes of anti-tuberculosis agents 
 The diarylquinoline R207910 (also known as TMC207) is a promising 
member of a new class of anti-mycobacterial agents. TMC207 was demonstrated 
to have high bactericidal activity when combined with first- or second-line 
antituberculous drugs [25]. The target and mechanism of action is different from 
those of other anti-TB agents implying low probability of cross-resistance with 
existing TB drugs. TMC207 is postulated to inhibit the proton pump of the 
M. tuberculosis adenosine triphosphate (ATP) synthase that is the main source of 















 Mycobacteria produce a wide array of complex fatty acids, such as 
mycocerosic acid and mycolic acids, not found in mammalian cells. While the 
synthesis of fatty cids occurs in all living organisms, mycobacteria posses 
accessory fatty acid synthase (FAS) enzymes with specialized substrate and 
product specificities and are considered as attractive target for TB drug 
development. β-Ketoacyl synthase (KAS) is responsible for the fatty acids 
synthesis, and catalyzes the most mechanistically complex of the sequences of 
FAS reactions. A new class of compounds designed to inhibit the β -ketoacyl 
synthase reaction of fatty acid synthesis have been developed. Acetamides 










 Oxazolidinones are a new class of antibacterial protein synthesis inhibitors 
with inhibition uniquely in the initiation phase of protein synthesis. Linezolid is 
the first oxazolidinone to be developed and approved to treat single or multiple 
resistant grampositive bacterial infections. In vitro studies have shown good 
activity of linezolid against M. tuberculosis, including MDR strains, but 
prolonged use of linezolid in the treatment of MDR TB frequently caused 
significant toxicity including anemia and peripheral neuropathy. Although 
oxazolidinones have promising potential for the treatment of MDR TB, more 
extensive clinical studies are needed to evaluate their efficacy and toxicity, as well 















 A particularly promising candidate for TB treatment is nitroimidazopyran 
PA824, derived from 5-nitroimidazole. PA824 is a prodrug that requires 
activation by a bacterial F420-dependent glucose-6-phosphate dehydrogenase and 
nitroreductase to activate components that then inhibit bacterial mycolic acid and 
protein synthesis. Additional studies are needed to evaluate PA824 in terms of its 
ability to shorten TB therapy in combination with other drugs without significant 
relapse, drug resistance or toxixity. PA824 is currently being evaluated in clinical 










 Other recently discovered chemical structures with the antituberculous 
potential include thiolactomycin, trypanthrin [16], 5-arylidene-2-thiohydantoins, 
benzoxazoles, benzothiazoles, benzoic acid hydrazones, chalcones, coumarins, 
purines [27], to name at least some. Carbohydrates and various marine 
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compounds have also been tested for antituberculous activity [16, 27]. Drugs used 
for treatment of other diseases, such as antifungal azoles and phenothiazines have 
good anti-tuberculosis activity and could be candidates for further evaluation for 
the treatment of TB [28]. 
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2.3. Mycoses and possibilities to manage them 
2.3.1. Mycoses 
 Most fungal infections (mycoses) involve superficial invasion of the skin 
or the mucous membranes of body orifices. These infections are divided into two 
etiologic groups: 
 the dermatophytoses (tinea infections), which are contagious 
superficial epidermal infections caused by various Epidermophyton, 
Microsporum and Trichophyton species 
 mycoses caused by pathogenic saprophytic yeasts, which are 
contagious and usually superficial infections involving the skin and  
mucous membranes. 
 Some species of saprophytic fungi (e.g. Aspergilllus, Candida and 
Cryptococcus species) under certain conditions are capable of invading deeper 
body cavities and causing systemic mycoses. Such infections may become serious 
and occasionally life-threatening, and they are frequently difficult to treat [20]. 
 
2.3.2. Fungi 
 All living things can be classified into one of five fundamental kingdoms 
of life, and the term fungus refers generically to all members of the kingdom 
Fungi. There are more than a million species of fungi, but only about 400 cause 
diseases relevant to man, animals, or plants. Fungi, including those pathogenic to 
humans and animals, are eukaryotic microorganisms. Classically, there are two 
broad groups of fungi: yeasts and moulds. Yeasts reproduce principally by 
budding (or fission) and moulds reproduce principally by elongation at the tips of 
filamentous growth forms. All fungal genera of medical importance can be placed 
into one of five sexual groups, even if sexual reproduction has not been observed. 
These groups correspond to the five phyla of the kingdom Fungi and are: 
 the ascomycetes (Phylum Ascomycota) 
 basidiomycetes (Phylum Basidiomycota) 
 zygomycetes (Phylum Zygomycota) 
 chytridiomycetes or chytrids (Phylum Chytridiomycota) 
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 Fungi Imperfecti 
 The first four groups are the true sexual groups (or phyla) because they are 
characterized by the production of sexual spores known as ascospores, 
basidiospores, zygospores, and oospores, respectively. Fungi that infect people 
come from all the groups except the chytridiomycetes. The chytrids are important 
as causes of diseases in agriculture and in lower cold-blooded animals. The 
asexual genera of the Fungi Imperfecti (also sometimes known as the phylum 
Deuteromycota) are different from the known sexual genera in that a sexual form 
is not known. Some genera are classified as dematiaceous, meaning that melanin 
in the cell walls of its conidia, hyphae, or both results in a darkly colored fungus 
[31]. 
 
2.3.3. Management of mycoses 
2.3.3.1 Chemotherapy 
 So far, chemotherapy has been the only possibility to manage mycoses. 
The selection of a suitable drug is dependent on the type of the disease. 
Superficial mycoses have been most often treated the non-specific antifungal 
agents derived from antiseptics. Fatty acids in perspiration have been found to be 
fungistatic, and this discovery has led to the introduction of fatty acids in therapy. 
The use of copper and zinc salts provides the added antifungal activity of the 
metal ion. Aromatic acids, especially salicylic acid, which also has a useful 
keratolytic action, and its derivatives are employed for their topical fungistatic 
effect. A variety of alkylated or halogenated phenols and their derivatives are 
useful for the treatment of local fungal infections. The antifungal activity of the 
aforementioned compounds is largely confined to local dermatophytic infections 
[20]. 
 The treatment of systemic mycoses has acquired increased importance in 
recent years as a result of the increased incidence of opportunistic yeast infections 
in immunocompromised patients. The widespread use of immunosuppressants 
following organ transplant operations and the AIDS epidemic have been major 
contributions to this situation [20, 31]. Clinical needs for novel antifungal agents 
have altered steadily with the rise and fall of AIDS-related mycoses, and the 
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change in spectrum of fatal disseminated fungal infections that has accompanied 
changes in therapeutic immunosuppressive therapies [32].  
 The targets of all antifungal agents used in the clinic (and of some agents 
that entered or approached clinical development but have not been marketed) are 
summarized in Figure 2. This figure shows that, contrary to occasional pessimistic 
comments, a considerable diversity of antifungal targets already exists. 
Nevertheless, in terms of numbers of classes of agents that can be used to treat 
life-threatening mycoses, the targets are heavily focused, directly or indirectly, on 
the cell envelope (wall and plasma membrane), and particularly on the fungal 
membrane sterol, ergosterol, and its biosynthesis. Targets elsewhere in the cell 
would therefore be a welcome innovation for systemically bioavailable antifungal 
agents. The search for new molecular targets for antifungals has generated 
considerable research using modern genomic approaches, so far without 












2.3.3.1. Current therapy 
 Examples of non specific antifungal agents used for local treatment are 





































methylrosanilinium chloride  
Figure 3. Examples of non specific antifungal agents used for local treatment. 
  
 Deep dermatophytic infections, resistant to topical therapy, maybe treated 
systematically. The earliest inhibitory agent specified to fungal species was 
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griseofulvin. The precise mechanism of this compound is still unknown, but the 
favoured explanation is that it interferes with microtubule assembly. The selective 
toxicity of griseofulvin for fungi is only moderate (liver toxicity is recognized as 
an occasional hazard), and its spectrum of action is mainly restricted to the 












 Flucytosine (5-fluorocytosine, 5-FC) is an antimetabolite type of 
antifungal drug. It is chemically 4-amino-5-fluoropyrimidin-2-one It is activated 
by deamination within the fungal cells to 5-fluorouracil. It inhibits fungal protein 
synthesis by replacing uracil in fungal RNA. Flucytosine also inhibits thymidylate 
synthetase via 5-fluorodeoxyuridine monophosphate and thus interferes with 











 Polyene antifungal agents include amphotericin B, natamycin and nystatin. 
Amphotericin B was isolated by Gold et al. from Streptomyces nodosus in 1955. 
It is an amphoteric compound. It composed of a hydrophilic polyhydroxyl chain 
along one side and a lipophilic polyene hydrocarbon chain on the other. It is 
poorly soluble in water. Amphotericin B is now available in four formulations. 
The classic amphotericin B deoxycholate formulation has been available since 
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1960 and is a colloidal suspension of amphotericin B. A bile salt, deoxycholate, is 
used as the solubilizing agent. This preparation has a number of toxicities that are 
partially ameliorated when a lipid carrier is used. Nonconventional formulations 
of amphotericin B for injection include liposomal amphotericin B, a colloidal 
dispersion of an amphotericin B and sodium cholesteryl sulfate complex, and a 
phospholipid complex. Amphotericin B binds to sterols, preferentially ergosterol. 
This binding disrupts osmotic integrity of the fungal membrane, resulting in 
leakage of intracellular potassium, magnesium, sugars, and metabolites and then 























 Natamycin is a polyene antifungal antibiotic produced by the growth of 
Streptomyces natalensis. It is used for the local treatment of oral candidiasis 
(lozenges) and fungal keratitis (ophthalmic suspension and ointment). Tablets 
have been given orally for the treatment of intestinal candidiasis. Natamycin has 
also been used topically for fungal skin infections and for candidal and 
trichomonal infections of the vagina [33]. 
 Nystatin is a polyene antifungal antibiotic used for the prophylaxis and 
treatment of candidiasis of the skin and mucous membranes. It interferes with the 
permeability of the cell membrane of sensitive fungi by binding to sterols, chiefly 
ergosterol. Its main action is against Candida spp. It has been used with anti-
bacterials in various regimens to suppress the overgrowth of gastrointestinal flora 






















 Imidazoles and triazoles are the largest class of antifungal agents in 
clinical use. Their main effect is to inhibit 14α-demethylation of lanosterol in the 
ergosterol biosynthetic pathway, but in some fungal species, they can also inhibit 
the subsequent 22-desaturase step. With ergosterol depleted and replaced with 
unusual sterols, the normal permeability and fluidity of the fungal membrane is 
altered, with secondary consequences for membrane-bound enzymes, such as 
those involved in cell wall synthesis. 
 The principal molecular target of azole antifungals is a cytochrome P450 – 
Erg11p or cyp51p, according to different gene based nomenclatures, which 
catalyses the oxidative removal of the 14α-methyl group of lanosterol and 
eburicol in fungi by a typical P450 mono-oxygenase activity [32]. 
 Although the first report of antifungal activity of an azole compound, 
benzimidazole, was already described in 1944, it was not until after the 
introduction of topical chlormidazole in 1958 that researchers became interested 
in the antifungal activity of azole compounds. In the late 1960´s, three new topical 


























 Miconazole, a phenethyl imidazole synthesized in 1969, was the first azole 
available for parenteral administration (although not before 1978). The drug has a 
limited spectrum of activity including dermatophytes, Candida spp., dimorphic 
fungi. The agent has proven to be an effective topical antifungal agent, but 
toxicity associated with the vehicle used for intravenous administration has 
limited its parenteral use. Miconazole has recently been withdrawn from the 
market.  
 In 1981, the Food and Drug Administration (FDA) approved the systemic 
use of ketoconazole. For almost a decade it would be regarded as the standard 
and was the only available oral agent for the treatment of systemic fungal 
infections. Until the introduction of the triazoles, ketoconazole was indicated as 
the drug of choice in chronic mucocutaneous candidiasis and as an effective 
alternative to amphotericin B in less severe (non-immunocompromised) cases of 
blastomycosis, histoplasmosis, coccidioidomycosis, and paracoccidioidomycosis. 
Ketoconazole has not been adequately evaluated in deep-seated candida infections 
or cryptococcosis and was ineffective in aspergillosis and mucormycosis. Over 
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the years, a number of clinically relevant shortcomings of this compound became 
evident. Ketoconazole was largely fungistatic and proved to be less effective in 
immunocompromised patients. Thus, the poor response rates and frequent 
recurrences of major fungal infections, as well as the toxicity associated with 
ketoconazole therapy, led to the search for a second chemical group of azole 
derivatives, namely the triazoles [34]. 
  In general, the triazoles demonstrate a broader spectrum of antifungal 
activity and reduced toxicity when compared with the imidazole antifungals. 
 Terconazole, the first triazole marketed for human use, was active in the 















 Fluconazole is a widely used bis-triazole antifungal agent with systemic 
action. As with other triazoles, it has five-membered ring structures containing 
three nitrogen atoms. It is active against Blastomyces dermatitidis, Candida spp., 
Coccidioides immitis, Cryptococcus neoformans, Epidermophyton spp., 
Histoplasma capsulatum, Microsporum spp., and Trichophyton spp. Resistance 
has developed in some Candida spp. following long-term prophylaxis with 














 Itraconazole is also a triazole antifungal agent. It has a slightly wider 
spectrum of activity than ketoconazole. It is active against Aspergillus spp., 
Blastomyces dermatitidis, Candida spp., Coccidioides immitis, Cryptococcus 
neoformans, Epidermophyton spp., Histoplasma capsulatum, Malassezia furfur, 
Microsporum spp., Paracoccidioides brasiliensis, Sporothrix schenckii, and 
Trichophyton spp. It also has some antiprotozoal activity against Leishmania spp. 
Acquired resistance to itraconazole is rare but ketoconazole-resistant strains of 

















 Of the three newest triazole antifungals, voriconazole and ravuconazole 
are structurally related to fluconazole, whereas posaconazole bears a close 
resemblance to itraconazole, but with dioxolene ring altered to a tetrahydrofuran. 
The structural differences might seem small, but they dictate antifungal potency 
and spectrum, bioavailibility and drug interaction and toxic potential [31, 32]. 
 Voriconazole, which is the first approved and so far the most fully 
characterised of the three new triazoles. Voriconazole has a broad spectrum of 
activity against all Candida species, including fluconazole-resistant strains, as 
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well as Aspergillus spp., Scedosporium spp., and Fusarium spp. and is even 











 Posaconazole also acts against a broad spectrum of susceptible fungi, 
(Candida spp., Aspergillus spp., Coccidioides immitis, Fonsecaea pedrosoi, and 
some species of Fusarium and zygomycetes). It used in the treatment of invasive 
aspergillosis, chromoblastomycosis, coccidioidomycosis, fusariosis, or mycetoma 




















 Ravuconazole is a triazole antifungal said to possess a broader spectrum 
of activity than fluconazole or itraconazole. It is under investigation for the 

















 Other sterol synthesis inhibitors are allylamines. The allylamines, notably 
terbinafine, inhibit squalene epoxidase, an early step in the pathway, with 
fungicidal consequences in susceptible species. These include many filamentous 
fungi but few pathogenic yeasts. Although terbinafine is not approved for 
treatment of visceral mycoses, there is interest in the possibility of combining 
terbinafine with other ergosterol synthesis inhibitors to achieve synergistic 
inhibitory effects [31, 32, 33]. Naftifine and butenafine are derivatives with 
actions similar to those of the terbinafine. They are applied topically once or twice 




















  Squalene epoxidase is also inhibited by antifungal agents of thiocarbamate 
type. Tolnaftate inhibits the growth of the dermatophytes, but is not active 
against Candida spp. It used topically in the treatment or prophylaxis of 
superficial dermatophyte infections and of pityriasis versicolor. Tolciclate and 

























 Amorolfine is a structurally unique, topically active antifungal agent, 
which possesses both fungistatic and fungicidal activity in vitro. Its spectrum of in 
vitro activity includes dermatophyte, dimorphic, some dematiaceous and 
filamentous fungi, and some yeasts. It interferes with ergosterol biosynthesis at 
two steps: the Δ14-reduction and the Δ7-8 isomerisation. As a consequence of this 
inhibition, the Δ14 sterol ignosterol is accumulated in the cell membrane and 
ergosterol is depleted. The cell wall thickness is significantly increased and chitin 
deposits are included inside and outside. In experimental models of systemic 
mycosis amorolfine shows no significant activity. This lack of systemic activity 











 Ciclopirox (used as olamine) is a hydroxypyridone antifungal that is 
structurally unrelated to other antifungal agents. It has a wide spectrum of 
antifungal activity. It inhibits most Candida, Epidermophyton, Microsporum, and 
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Trichophyton spp. and is also active against Malassezia furfur. It is applied 







 The echinocandins are fungal secondary metabolites comprising a cyclic 
hexapeptide core with a lipid side chain responsible for antifungal activity. 
Antifungal activity in the prototype, echinocandin B and aculeacin A, was 
discovered by random screening in the 1970´s. A modified form of echinocandin 
B, cilofungin, was developed to the point of phase 2 trials, but was abandoned 
when its formulation showed toxicity to the patients. In the late 1990´s, three 
echinocandine-class compounds, caspofungin, anidulafungin, and micafungin all 
entered clinical development. The target for the echinocandins is complex of 
proteins responsible for the synthesis of cell wall β-(1,3)-D-glucan 
polysaccharides. Echinocandins appear to demonstrate favourable activity in vitro 
against a variety of yeasts (including both C. albicans and non-albicans Candida) 
as well as selected moulds (including Aspergillus spp.). In general, all 
echninocandins demonstrate a favourable safety profile and require once-daily 
parenteral administration. Their metabolism is independent of hepatic cytochrome 
P450 enzymes, which minimizes drug interactions [32, 42, 43]. 
 Caspofungin (approved 2001) is the first of these agents to be available 
and is approved for empirical antifungal therapy in febrile neutropenic patients, 
candidaemia and some forms of invasive candidiasis, and for management of 
invasive aspergillosis in patients refractory to or intolerant of other therapies. It is 








































 Micafungin was approved in 2005 for treatment of oesophageal 
candidiasis, and for the prophylaxis of fungal infections in haematopoietic stem 
cell transplant recipients. It is also in the treatment of aspergillosis. It is given as 











































 Anidulafungin was approved in 2006 for the treatment of candidemia, 
other forms of candida infections (intra-abdominal abscess and peritonitis), and 
esophageal candidiasis. It is a water soluble, semisynthetic, cyclic lipopeptide 
derivative of echinocandin B. Like all echinocandins, anidulafungin is only 
available as an intravenous formulation due to its large molecular weight. Its long 
half-life allows for once-daily dosing intervals. The efficacy of anidulafungin 
against specific fungal pathogenes varies. Anidulafungin compares favorably with 
other antifungal agents. Because of the fungistatic effect of anidulafungin against 
Aspergillus, this antifungal may prove to be beneficial when used as part of 



































 Aminocandin (HMR-3702, IP-960) is an investigational agent, with 
published experience limited to in vitro studies and animal models of infection 
[42]. 
 
2.3.3.2. New structural classes of antimycotic agents 
 In recent years a new threat has emerged due to the appearance of fungal 
strains with multidrug resistance. The substances with the different target 
structures have been studied intensively as potential new antimycotic agents [46, 
47]. According to the mechanism of effect they can be classified as 
 novel inhibitors of β-(1,3)-D-glucan synthesis 
 inhibitors of chitin synthesis 
 selective inhibitors of proteosynthesis 
 compounds exerting antifungal activities via lysis  
  
 Novel inhibitors of β-(1,3)-D-glucan synthesis are represented by 
papulacandins, a class of unusual spirocyclic natural products originally isolated 
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from Papularia sphaerosperma. The papulacandins displayed potent in vitro 
activity against yeasts, particularly C. albicans as well as modest efficacy in vivo 
via s. c. administration (e.g. populacandin B). Oral activity against systematic 
fungal infections has remained elusive. Since the discovery of papulacandins, 
other structurally related natural products have been reported, including 
























 FR-901469 belongs to a new family of natural products inhibiting fungal 
β-(1,3)-D-glucan synthesis. FR-901469 has shown potent antifungal activity in the 
murine systemic candidiasis model. However, hepatotoxicity was observed with 
this compound after multiple dosing in mice. In light of this drawback, chemical 
modifications were inducted on FR-901469 with the aim of improving the in vivo 
antifungal activity and reducing hepatotoxicity [48, 49]. 
 Polyoxins and nikkomycins belong to the agents affecting chitin 
synthesis. They are natural products capable of inhibiting chitin synthase, an 
enzyme that catalyzes the polymerization of N-acetylglucosamine to form a major 
component of the fungal cell wall. Chitin is absent in vertebrates, hence these 
compounds lack the mammalian toxicity. All these agents are nucleoside peptides. 
Direct clinical application of the natural peptidyl nucleosides is compromised by 
48 
 
their attenuated in vivo activity, apparently due to their hydrolytic lability and 
inefficient fungal cell wall permeability. Thus, extensive efforts have focused on 
synthesis of natural peptidyl nucleosides, their components and analogues in 
anticipation of establishing useful structure-activity-relationships (SAR) for the 




































 The sordarin antifungal class, although not developed for clinical use, 
merits mention among the new mechanisms of action. They inhibit protein 
synthesis by blocking the function of fungal translation Elongation Factor 2 
(EF2). The class was discovered by routine screening but was abandoned in the 
early 1970´s. Interest in sordarins was re-awakened as a result of a prospective 
screen for inhibitors of C. albicans protein synthesis in vitro, which pinpointed the 
nature of the sordarin antifungal effect. When refined experimentation revealed 
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EF2 as the specific target of the sordarins, the result engendered surprise because 
C. albicans EF2 displays more than 85% amino acid sequence identity to the 
human equivalent, and EF2 would never have emerged as a potential target from 
genomics-based screening. Different sordarin derivatives have different spectra of 
susceptible species, for reasons that are not yet clear. This might reflect problems 
of penetration of these agents into target fungi. Nevertheless, their high specificity 
for the fungal target and the relative ease with which new sordarin variants can be 
synthesized holds promise for positive future developments with this series [32, 
53]. 
 Syringotoxins, syringomycins, syringostatins and pseudomycins are 
cyclic lipodepsinonapeptides produced by the plant bacterium Pseudomonas 
syringae pv. syringae. These metabolites are phytotoxic and growth inhibitory 
against a broad spectrum of fungi. It has been shown that they target the fungal 
plasma membrane and alter several membrane functions. They are also known as 
necrosis-inducing lipodepsipeptide toxins. Members of the syringomycins class 
are pore-forming cytotoxins that act by promoting passive transmembrane ion flux 
[48, 54]. 
 The rising occurence of resistance should be coped with inhibitors of the 






















 Multidrug resistence in fungi can also be mediated by MDR1 
P-glycoprotein. Aureobasidins, produced by Aureobasidium pullulans, are cyclic 
depsipeptides. They were found to interfere with ATP-binding cassete 
transporters, particularly that of MDR1 P-glycoprotein. They exhibited potent 
antifungal activity against Candida spp. and C. neoformans, but not A. fumigatus. 
It was also found that aureobasidins inhibit inositol phosphorylceramide synthase, 
which has recently been identified as a potential target for the development of 
potential new antifungal drugs [32, 48, 55, 56]. 
 There are hundreds of potential antifungals with unknown mode of action, 
which are presently under study, e.g. viscosinamide, glomosporin, jaspamides, 
cyclolithistide A, halolitoralins and lobocyclamides [48, 57,58]. 
 New alternatives to treating mycoses are required to circumvent the often 
poorly efficient fungal treatments. Human trials using antibody mediated 
immunity are ongoing against C. albicans and C. neoformans infections. Other 
efforts favour the elicitation of protective cellular immune responses. One 
exciting discovery is the identification of good and bad antibodies that either 
protect or harm patients. Another challenge in vaccination against fungi is the 
protection of immunocompromised patients at risk. The challenge of the next 
several years remains to link the biological and ecological properties of the fungus 
with the immunosuppresive status of the host in order to understand virulence. 
There is no doubt that genomic and post genomic approaches will help our 
understanding of the multigenic character of virulence [59, 60]. 
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3.  EXPERIMENTAL  PART 
Commercially available substances were used for the preparation of 
arylmethylidenerhodanines:  
 2-methoxybenzaldehyde, purum (Fluka) 
 3-methoxybenzaldehyde (Sigma) 
 4-methoxybenzaldehyde, purum (Fluka) 
 2-bromobenzaldehyde, purum (Fluka) 
 pyridine-2-carboxaldehyde, 99% (Aldrich) 
 rhodanin, puriss. p. a. (Fluka) 
 
TLC was performed on Silufol UV 254 (Kavalier Votice) plates. Light petroleum 
+ ethyl acetate 60:40 (v/v) was used as a mobile phase. 
 
For analysis, the samples of compounds were dried 24 hours in the dessicator at 
1.33 kPa. 
  
Melting points were determined using Boëtius apparatus and are uncorrected. 
 
Elemental analyses were performed with the EA 1110 CHNS Analyzer (Carlo 
Erba). 
 
HPLC analyses were performed as follows: 
Separation module: Waters Alliance 2695 XE with the Millennium
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Chromatography Manager Software, Waters 2004.  
Column: Symmetry
®
 C18 5 m, 4.6  250 mm.  
Mobile phase: methanol + water 70:30 (v/v), flow 0.9 ml/min, injection 30 l 
Detection: Waters Photodiode Array Detector 2996, 210 nm 
 
IR spectra were recorded using the spectrophotometer NICOLET IMPACT 400. 









C-NMR spectra were recorded with the VARIAN Mercury-VxBB 
300. Chemical shifts are given in δ, ppm and interaction constants J in Hz. 
 



















 A mixture of 2-methoxybenzaldehyde (2.04 g; 0.015 mol), rhodanine (2.00 
g, 0.015 mol), concentrated ammonia solution (1.1 ml) and ethanol (15 ml) was 
heated under reflux condenser until all solid components dissolved. Solution of 
ammonium chloride (1.00 g) in 2 ml of hot (80 °C) distilled water was then added, 
and the reaction mixture was refluxed for 2 hours. After cooling, the separated 
solid was filtered through a sintered filter, washed with distilled water (50 ml) and 
then with 50% ethanol (50 ml). 
3.58 g (95%) of dry crude product was obtained. 
For analysis, the product was crystallized from absolute ethanol. 
 
Molecular weight: 251.32 
Appearance: yellow, crystalline solid 
Melting point: 258 °C  
Melting points reported previously  
 251 °C (configuration unknown, ethanol) [61] 
 198 – 200 °C (configuration unknown, methanol) [61]  
Elemental analysis for C11H9NO2S2: 
 % C % H % N % S 
Calculated: 52.57 3.61 5.57 25.52 
Found: 52.87 3.34 5.67 25.09 
HPLC purity: 98.33 % 
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IR spectrum (KBr): 3447, 3141(NH); 1705 (C=O) 
1
H NMR (300 MHz, DMSO):  13.76 (1H, bs, NH), 7.78 (1H, s, CH), 7.53 –7.44 
(1H, m, H4´), 7.37 (1H, dd, J = 7.7 Hz, J = 1.7 Hz, H6´), 7.14 (1H, d, J= 7.7 Hz, 
H3´), 7.08 (1H, t, J = 7.7 Hz, H5´), 3.88 (3H, s, OCH3) 
13
C NMR (75 MHz, DMSO)  196.3, 169.6, 158.3, 133.2, 129.9, 126.9, 125.5, 
121.5, 121.4, 112.2, 56.0 
 





















 A mixture of 3-methoxybenzaldehyde (2.04 g, 0.015 mol), rhodanine (2.00 
g, 0.015 mol), concentrated ammonia solution (1.1 ml) and ethanol (15 ml) was 
heated under reflux condenser until all solid components dissolved. Solution of 
ammonium chloride (1.00 g) in 2 ml of hot (80 °C) distilled water was then added, 
and the reaction mixture was refluxed for 2 hours. After cooling, the separated 
solid was filtered through a sintered filter, washed with distilled water (50 ml) and 
then with 50% ethanol (50 ml). 
3.06 g (81%) of dry crude product was obtained. 
For analysis, the product was crystallized from absolute ethanol. 
 
Molecular weight: 251.32 
Appearance: yellow, crystalline solid 
Melting point: 235 °C 
Melting points reported previously  
 232 °C (configuration unknown, ethanol) [61]  
 227 °C (configuration unknown, acetic acid) [61] 
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 229 – 230 °C (configuration unknown, nitrobenzene) [61] 
 165 – 170 °C (configuration unknown, methanol) [61] 
Elemental analysis for C11H9NO2S2: 
 % C % H % N % S 
Calculated: 52.57 3.61 5,57 25.22 
Found: 52.73 5.43 5.65 25.87 
 
HPLC purity: 93.71% 
IR spectrum (KBr): 3151 (NH); 1698 (C=O) 
1
H NMR (300 MHz, DMSO): 13.82 (1H, bs, NH), 7.60 (1H, s, CH), 7.44 (1H, t, 
J = 8.1 Hz, H5´), 7.16 – 7.03 (3H, m, H2´, H4´, H6´), 3.79 (3H, s, OCH3) 
13
C NMR (75 MHz, DMSO):  195.8, 169.5, 159.9, 134.5, 131.8, 130.7, 126.0, 
122.6, 116.9 115.8, 55.5 
 




















 A mixture of 4-methoxybenzaldehyde (2.04 g, 0.015 mol), rhodanine (2.00 
g, 0.015 mol), concentrated ammonia solution (1.1 ml) and ethanol (15 ml) was 
heated under reflux condenser until all solid components dissolved. Solution of 
ammonium chloride (1.00 g) in 2 ml of hot (80 °C) distilled water was then added, 
and the reaction mixture was refluxed for 2 hours. After cooling, the separated 
solid was filtered through a sintered filter, washed with distilled water (50 ml) and 
then with 50% ethanol (50 ml). 
3.40 g (90%) of dry crude product was obtained. 
For analysis, the product was crystallized from absolute ethanol. 
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Molecular weight: 251.32 
Appearance: yellow, crystalline solid 
Melting point: 260 – 261 °C  
Melting points reported previously  
 262 °C (Z-isomer) [61] 
 257 – 259 °C (Z-isomer, ethanol) [61] 
 242.5 °C (Z-isomer, DMF) [61] 
 233 – 235 °C (E-isomer, ethyl acetate, hexane) [61] 
 261 – 262 °C (configuration unknown, water, DMF) [61] 
 252 °C  (configuration unknown) [61] 
 250 – 251 °C (configuration unknown, ethanol) [61] 
 249 – 254 °C (configuration unknown, ethanol) [61] 
 248 – 251 °C (configuration unknown) [61] 
 245 °C (configuration unknown) [61] 
 230 – 242 °C (configuration unknown, acetic acid) [61] 
 207 – 208 °C (configuration unknown, methanol) [61] 
Elemental analysis for C11H9NO2S2: 
 % C % H % N % S 
Calculated: 52.57 3.61 5.57 25.52 
Found: 52.25 3.60 5.75 27.94 
 
HPLC purity: 86.24% 
IR spectrum (KBr): 3448, 3137 (NH); 1687 (C=O) 
1
H NMR (300 MHz, DMSO): 13.72 (1H, bs, NH), 7.59 (1H, s, CH), 7.58 – 7.50 
(2H, m, AA´, BB´, H2´, H6´), 7.13 – 7.05 (2H, m, AA´, BB´, H3´, H5´), 3.82 (3H, 
s, OCH3) 
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 A mixture of 4-bromobenzaldehyde (2.78 g, 0.015 mol), rhodanine (2.00 
g, 0.015 mol), concentrated ammonia solution (1.1 ml) and ethanol (15 ml) was 
heated under reflux condenser until all solid components dissolved. Solution of 
ammonium chloride (1.00 g) in 2 ml of hot (80 °C) distilled water was then added, 
and the reaction mixture was refluxed for 2 hours. After cooling, the separated 
solid was filtered through a sintered filter, washed with distilled water (50 ml) and 
then with 50% ethanol (50 ml). 
4.15 g (92%) of dry crude product was obtained. 
For analysis, the product was crystallized from absolute ethanol. 
 
Molecular weight: 300.19 
Appearance: yellow, crystalline solid 
Melting point: 238 °C 
Melting points reported previously 
 231 °C (Z-isomer, ethanol) [62] 
 238 °C (configuration unknown) [61] 
 237 – 238 °C (configuration unknown, acetic acid) [61] 
 219 °C (configuration unknown) [61] 
 219 °C (configuration unknown, ethanol) [61] 
Elemental analysis for C10H6BrNOS2: 
 % C % H % N % S 
Calculated: 40.01 2.01 4.67 21.36 
Found: 39.95 1.87 4.64 21.78 
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HPLC purity: 89.11% 
IR spectrum (KBr): 3442, 3150 (NH); 1708 (C=O) 
1
H NMR (300 MHz, DMSO): 7.76 – 7.69 (2H, m, AA´, BB´, H2´, H6´), 7.60 
(1H, s, CH), 7.55 – 7.49 (2H, m, AA´, BB´, H3´, H5´)  
13
C NMR (75 MHz, DMSO):  195.6, 169.5, 132.6, 132.4, 132.4, 130.5, 126.5, 
124.5 
 





















 A mixture of pyridine-2-carboxaldehyde (1.61 g, 0.015 mol), rhodanine 
(2.00 g, 0.015 mol), concentrated ammonia solution (1.1 ml) and ethanol (15 ml) 
was heated under reflux condenser until all solid components dissolved. Solution 
of ammonium chloride (1.00 g) in 2 ml of hot (80 °C) distilled water was then 
added, and the reaction mixture was refluxed for 2 hours. After cooling, the 
separated solid was filtered through a sintered filter, washed with distilled water 
(50 ml) and then with 50% ethanol (50 ml). 
2,35 g (70%) of dry crude product was obtained. 
For analysis, the product was crystallized from absolute ethanol. 
 
Molecular weight: 222.29  
Appearance: green-yellow, crystalline solid 
Melting point: 269 – 272 °C 
Melting points reported previously  
 257 – 260 °C (Z-isomer, ethanol) [61] 
 253 – 258 °C (configuration unknown, methanol) [61] 
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 247 – 250 °C (configuration unknown, ethanol) [61] 
 243 – 245 °C (configuration unknown, ethanol) [61] 
Elemental analysis for C9H6N2OS2: 
 % C % H % N % S 
Calculated: 48.63 2.72 12.60 28.85 
Found: 48.26 2.65 12.82 28.90 
 
HPLC purity: 93.99% 
IR spectrum (KBr): 3412 (NH); 1726 (C=O) 
1
H NMR (300 MHz, DMSO): 13.66 (1H, bs, NH), 8.77 (1H, d, J = 4.7 Hz, H6´), 
7.94 (1H, dt, J = 7.6 Hz, J = 1.8 Hz, H4´), 7.88 (1H, d, J = 7.6 Hz, H3´), 7.67 (1H, 
s, CH), 7.45 – 7.39 (1H, m, H5´) 
13




3.6. Evaluation of in vitro antifungal activity 
 Antifungal activity of all compounds against Candida albicans ATCC 
44859, Candida tropicalis 156, Candida krusei E 28, Candida glabrata 20/I, 
Trichosporon asahii 1188, Aspergillus fumigatus 231, Absidia corymbifera 272 
and Trichophyton mentagrophytes 445 was evaluated by the microdilution broth 
method. All strains were subcultured on Sabouraud dextrose agar (SDA, Difco) 
and maintained on the same medium at 4 °C. Prior to testing, each strain was 
passaged onto SDA and fungal inocula were prepared by suspending yeasts or 
conidia or sporangiospores in sterile 0.85% saline. The cell density was adjusted, 
using the Bürker´s chamber, to yield a stock suspension of (1.0 ± 0.2) × 10
5
 
CFU/ml. The final inoculum was made by 1:20 dilution of the stock suspension 
with the test medium. The compounds were dissolved in dimethyl sulfoxide 
(DMSO) and antifungal activity was determined in the tissue culture medium 
RPMI 1640 (Sevapharma, Prague, Czech Republic) buffered to pH 7.0 with 0.165 
M 3-morpholinopropane-1-sulfonic acid (Sigma). Controls were included as well. 
The final concentration of DMSO in the test medium did not exceed 1% (v/v) of 
the total solution composition. The minimum inhibitory concentration (MIC), 
defined as 80% inhibition of fungal growth compared to control, were determined 
after 24 and 48 h of static incubation at 35 °C. In the case of T. mentagrophytes 
the MICs were recorded after 72 and 120 h. Amphotericin B and fluconazole were 
used as reference antifungal drugs. The results are given in Table 1.  
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Table 1. Minimum inhibitory concentrations of the tested compounds 
STRAIN 
COMPOUND – MIC/IC80 (µmol.l
-1
) 
3.1. 3.2. 3.3. 3.4. 3.5. AMP-B FLU 
CA 
24h >125 >125 >500  62.5 62.5 0,002 0,82 
48h >125 >125 >500 >125 >125 0,068 1,63 
CT 
24h >125 >125 >500 >125 >125 0,068 1,63 
48h >125 >125 >500 >125 >125 0,068 > 417,90 
CK 
24h >125 >125 >500 >125 >125 0,135 52,24 
48h >125 >125 >500 >125 >125 0,135 104,47 
CG 
24h >125 >125 >500 >125 >125 0,034 13,06 
48h >125 >125 >500 >125 >125 0,135 52,24 
TA 
24h >125 >125 >500 >125 >125 1,082 3,26 
48h >125 >125 >500 >125 >125 2,164 6,53 
AF 
24h >125 >125 >500 >125 >125 0,271 > 417,90 
48h >125 >125 >500 >125 >125 0,135 > 417,90 
AC 
24h >125 >125 >500 >125 >125 1,082 > 417,90 
48h >125 >125 >500 >125 >125 2,164 > 417,90 
TM 
72h >125 >125 250 31.25 >125 1,082 26,12 




4.  DISCUSSION 
 In the theoretical part of my diploma thesis some issues concerning 
tuberculosis and mycoses are discussed. Experimental part focused on the 
preparation of the following compounds: 
 5-(2-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.1.) 
 5-(3-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.2.) 
 5-(4-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.3.) 
 5-(4-bromobenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.4.) 
 5-pyridin-2-ylmethyliden-2-thioxo-1,3-thiazolidin-4-one (3.5.) 
 All these compounds have been reported in literature previously. 
Nonetheless, their characterization has been incomplete so far. NMR spectra are 
often not available, and configuration on the exocyclic double bond has only been 
determined in some cases [61, 62]. 
 5-(2-Methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one has been known 
since 1941 [63]. 5-(3-Methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one was 
prepared by Avison and Morrison in 1950 [64]. Since then, these compounds have 
been prepared by many other research groups, but to the best of my knowledge 
their antifungal effects have not been studied so far [61, 62]. 
 5-(4-Methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one was reported at 
the beginning of the 20
th
 century [61, 65] and 5-(4-bromobenzylidene]-2-thioxo-
1,3-thiazolidin-4-one has been known since 1948 [66]. Antifungal activity of 
these two compounds was studied by Brown et al. [67] and Sortino et al. [68]. 
 Regarding the heterocyclic derivative, 5-pyridin-2-ylmethyliden-2-thioxo-
1,3-thiazolidin-4-one, the synthetic priority belongs to Lapière [69], and its 
antifungal effects were studied by Allan and co-workers [70] and Sortino et al. 
[68]. 
 Arylmethylidenerhodanines can form two isomers. According to 
references, syntheses of these compounds result in Z-izomer. Configuration on the 





signals of the methine-group hydrogens for Z-izomers are more downfield 















 The signals of these hydrogens in the rhodanine derivatives studied in the 
present paper were calculated and compared with the reported and experimental 
values (Table 2). 
 
Table 2. Comparison of 
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CS ChemOffice 7.0 (CambridgeSoft, Cambridge, MA, U.S.A.); 
 b 
CS ChemOffice 10.0 
(CambridgeSoft, Cambridge, MA, U.S.A.); 
c 
Z-isomer [68]  
 
 Based on the experimental 
1
H-NMR signals, it can be concluded that all 
arylmethylidenerhodanines reported in the present paper were obtained as single 
isomers. Comparing the calculated, reported and experimental data shows that 
5-(4-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.3) and 5-pyridin-2-
ylmethyliden-2-thioxo-1,3-thiazolidin-4-one (3.5.) have Z-configuration. In case 
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of the remaining products, a definitive determination of the configuration would 
require additional experiments. 
 The products have already been tested for antifungal effects. The assay 
was performed at the Department of Biological and Medical Sciences of the 
Faculty of Pharmacy in Hradec Králové. Unfortunately, no interesting antifungal 
activity was found. This in agreement with the results of Sortino et al. who studied 
the same compounds simultaneously with me and found that a substituted benzene 
ring is a necessary moiety for these compounds to possess antifungal activity, 
whilst the pyridine analogues are inactive. The type of substituent on the benzene 
ring appears to play an important role. The most active compounds were F- and 
CF3-substituted benzylidenerhodanines. On the other hand, rhodanines with Br 
atom or with donor substituents (CH3, OCH3, O-CH2-O) showed marginal or null 
activity [68]. 
 The antimycobaterial properties of the compounds 3.1. – 3.5. will be tested 
later, preferably in the Tuberculosis Antimicrobial Acquisition and Coordinating 




5.  CONCLUSIONS 
The following compounds were prepared within my experimental work: 
 5-(2-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.1.) 
 5-(3-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.2.) 
 5-(4-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.3.) 
 5-(4-bromobenzylidene]-2-thioxo-1,3-thiazolidin-4-one (3.4.) 
 5-pyridin-2-ylmethyliden-2-thioxo-1,3-thiazolidin-4-one (3.5.) 
The compounds were obtained as single isomers, most probably with 
Z-configuration on the exocyclic double bond. 
They have been tested for antifungal effects against 8 pathogenic strains of fungi, 
but did not exhibit an interesting activity. In the future, their antimycobacterial 
potency will be evaluated. 
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Abstract 
 In the theoretical part of my diploma thesis some issues concerning 
tuberculosis and mycoses are discussed. Experimental part focused on the 
preparation of the following compounds  
 5-(2-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one  
 5-(3-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one 
 5-(4-methoxybenzylidene]-2-thioxo-1,3-thiazolidin-4-one 
 5-(4-bromobenzylidene]-2-thioxo-1,3-thiazolidin-4-one  
 5-pyridin-2-ylmethyliden-2-thioxo-1,3-thiazolidin-4-one. 
 The compounds were prepared by the condensation of rhodanine with 
aromatic aldehydes in ethanol using a mixture NH4OH/NH4Cl as the catalyst. 
Their purity was checked by the elemental analysis and HPLC. The products were 
characterized by IR and NMR spectra. 
 The susceptibility of 8 pathogenic fungal strains (Candida albicans ATCC 
44859, Candida tropicalis 156, Candida krusei E 28, Candida glabrata 20/I, 
Trichosporon asahii 1188, Aspergillus fumigatus 231, Absidia corymbifera 272 
and Trichophyton mentagrophytes 445) to these substances was determined by the 
microdilution broth method. No interesting activity was found. The compounds 
will further be tested for antimycobacterial effects. 
 
 
 
 
